165 related articles for article (PubMed ID: 20965299)
1. A novel adjuvant for vaccine development in the aged.
Morgan EL; Thoman ML; Sanderson SD; Phillips JA
Vaccine; 2010 Dec; 28(52):8275-9. PubMed ID: 20965299
[TBL] [Abstract][Full Text] [Related]
2. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.
Hung CY; Hurtgen BJ; Bellecourt M; Sanderson SD; Morgan EL; Cole GT
Vaccine; 2012 Jun; 30(31):4681-90. PubMed ID: 22575167
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.
Morgan EL; Morgan BN; Stein EA; Vitrs EL; Thoman ML; Sanderson SD; Phillips JA
Vaccine; 2009 Dec; 28(2):463-9. PubMed ID: 19836478
[TBL] [Abstract][Full Text] [Related]
4. Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.
Phillips JA; Morgan EL; Dong Y; Cole GT; McMahan C; Hung CY; Sanderson SD
Bioconjug Chem; 2009 Oct; 20(10):1950-7. PubMed ID: 19788175
[TBL] [Abstract][Full Text] [Related]
5. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
6. OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis.
Yanase N; Toyota H; Hata K; Yagyu S; Seki T; Harada M; Kato Y; Mizuguchi J
Vaccine; 2014 Oct; 32(45):5918-24. PubMed ID: 25211769
[TBL] [Abstract][Full Text] [Related]
7. The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.
Liu X; Wetzler LM; Massari P
Vaccine; 2008 Feb; 26(6):786-96. PubMed ID: 18191311
[TBL] [Abstract][Full Text] [Related]
8. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice.
Maletto B; Rópolo A; Morón V; Pistoresi-Palencia MC
J Leukoc Biol; 2002 Sep; 72(3):447-54. PubMed ID: 12223511
[TBL] [Abstract][Full Text] [Related]
9. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant effect of water-soluble polysaccharide (PAP) from the mycelium of Polyporus albicans on the immune responses to ovalbumin in mice.
Sun Y; Liu J
Vaccine; 2008 Jul; 26(31):3932-6. PubMed ID: 18555566
[TBL] [Abstract][Full Text] [Related]
12. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
13. Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.
Karuturi BV; Tallapaka SB; Phillips JA; Sanderson SD; Vetro JA
Clin Immunol; 2015 Dec; 161(2):251-9. PubMed ID: 26111481
[TBL] [Abstract][Full Text] [Related]
14. Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.
Tallapaka SB; Karuturi BVK; Yeapuri P; Curran SM; Sonawane YA; Phillips JA; David Smith D; Sanderson SD; Vetro JA
Int J Pharm; 2019 Jun; 565():242-257. PubMed ID: 31077762
[TBL] [Abstract][Full Text] [Related]
15. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
[TBL] [Abstract][Full Text] [Related]
16. EPSAH, an exopolysaccharide from Aphanothece halophytica GR02, improves both cellular and humoral immunity as a novel polysaccharide adjuvant.
Zhu L; Zhang F; Yang LJ; Ge Y; Wei QF; Ou Y
Chin J Nat Med; 2016 Jul; 14(7):541-8. PubMed ID: 27507205
[TBL] [Abstract][Full Text] [Related]
17. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
[TBL] [Abstract][Full Text] [Related]
18. Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice.
Gupta A; Khajuria A; Singh J; Singh S; Suri KA; Qazi GN
Int Immunopharmacol; 2011 Aug; 11(8):968-75. PubMed ID: 21371582
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma inductive effect of liposomes as an immunoadjuvant.
Aramaki Y; Suda H; Tsuchiya S
Vaccine; 1995 Dec; 13(18):1809-14. PubMed ID: 8701598
[TBL] [Abstract][Full Text] [Related]
20. A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection.
Wilson HL; Kovacs-Nolan J; Latimer L; Buchanan R; Gomis S; Babiuk L; van Drunen Littel-van den Hurk S
Vaccine; 2010 Dec; 28(52):8288-99. PubMed ID: 20959153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
